Loading stock data…
LCTX
$1.23+0.01 (+1.24%)
After Hours$1.22-0.01 (-0.41%)· Last close Jun 9
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lineage Cell Therapeutics, Inc. in the Healthcare sector is trading at $1.23 with a market capitalization of $299M. Wall Street consensus targets $5.50 (6 analysts), implying a +349.0% move over the next 12 months. The stock is currently 41% below its 52-week high of $2.09, remaining 23.0% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +349.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.23
Potential Downside
0%
Whystock Fair Value$1.23
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment e...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$299.16M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-119.18%
Volume
Today's trading volume
1.34M
Recent News
How The Lineage Cell Therapeutics (LCTX) Story Is Shifting With New Data And Analyst Targets
Lineage Cell Therapeutics is back on investor radar as bullish analysts lift their price target from US$4.50 to US$5.50 per share, pointing to a different view on where the stock could sit if their models play out. These higher targets are being framed as better aligned with updated assumptions on revenue potential and earnings power. At the same time, more cautious voices still point to execution risk and the gap between current fundamentals and those projections. As you read on, you will...
Promising Penny Stocks To Consider In May 2026
The United States market has shown robust performance, with a 1.2% increase over the last week and a substantial 29% rise over the past year, alongside an optimistic forecast for earnings growth of 17% annually. In light of these conditions, investors might find opportunity in stocks that balance affordability with potential growth, particularly those often labeled as penny stocks. While the term may seem outdated, these smaller or newer companies can offer intriguing prospects when backed by...
Lineage Cell Therapeutics Q1 Earnings Call Highlights
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program in geographic atrophy, a newly launched corneal endothelial cell program called COR1, and ongoing ma
Lineage Cell Therapeutics Inc (LCTX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...
Lineage Cell Therapeutics Inc (LCTX) showcases promising program developments and a robust cash position, despite facing operational challenges and increased net loss.
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Lineage Cell (LCTX) delivered earnings and revenue surprises of -50.00% and -46.53%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?